Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anna Wu
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImaginAb, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Anna Wu is the Principal Investigator on this research project, and holds a privately-held equity interest in ImaginAb, Inc. In addition Dr. Wu is a Board of Directors member and consultant for ImaginAb, Inc, and is compensated (b)(4) for this service. The City of Hope Conflict of Interest and Commitment Committee (“COICC”) has determined that Dr. Wu’s interests in ImaginAb, Inc. relate to the grant as the research centers on developing and evaluating the ability of dually labeled PSCA fragments to image prostate and pancreatic cancers for combined PED and fluorescent guided therapy while ImaginAb, Inc. has a similar business focus and develops imaging products.
Multifunctional immunoPET tracers for pancreatic and prostate cancer
RELEVANCE TO PUBLIC HEALTH Prostate and pancreatic cancers are among the most common and difficult to treat cancers, with major challenges in accurately diagnosing and staging disease, as well as monitoring response to therapy. One major barrier to progress is the absence of effective molecular imaging tracers/tools that can guide patient management. We are developing novel cancer-specific molecular imaging agents based on engineered antibodies that recognize PSCA, a cell surface biomarker expressed in pancreatic and prostate cancer, that can be used pre-operatively for staging, intraoperatively during surgery, and can ultimately be used to deliver targeted therapies directly to tumors.
Filed on December 05, 2018.
Tell us what you know about Anna Wu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Anna Wu filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Anna Wu | University of California Los Angeles | Conflict of Interest | ImaginAB Inc | $450,000 - $499,999 |
| Anna Wu | Beckman Research Institute/city of Hope | Conflict of Interest | ImaginAb, Inc. | $20,000 - $39,999 |
| Anna Wu | University of California Los Angeles | Conflict of Interest | ImaginAB Inc | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.